0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Exploring barriers and facilitators to participation of male-to-female transgender persons in preventive HIV vaccine clinical trials.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Observed seroincidence and prevalence rates in male-to-female (MTF) transgender individuals highlight the need for effective targeted HIV prevention strategies for this community. In order to develop an effective vaccine that can be used by transgender women, researchers must understand and address existing structural issues that present barriers to this group's participation in HIV vaccine clinical trials. Overcoming barriers to participation is important for ensuring HIV vaccine acceptability and efficacy for the MTF transgender community. To explore barriers and facilitators to MTF transgender participation in preventive HIV vaccine clinical trials, the HIV Vaccine Trials Network conducted focus groups among transgender women in four urban areas (Atlanta, Boston, Philadelphia, and San Francisco). Barriers and facilitators to engagement of transgender women in preventive HIV vaccine clinical trials led to the following recommendations: (a) transgender cultural competency training, (b) creating trans-friendly environments, (c) true partnerships with local trans-friendly organizations and health care providers, (d) protocols that focus on transgender specific issues, and (e) data collection and tracking of transgender individuals. These results have implications for the conduct of HIV vaccine trials, as well as engagement of transgender women in research programs in general.

          Related collections

          Author and article information

          Journal
          Prev Sci
          Prevention science : the official journal of the Society for Prevention Research
          Springer Nature
          1573-6695
          1389-4986
          Jun 2014
          : 15
          : 3
          Affiliations
          [1 ] HVTN Social Scientist, HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, E3-300, Seattle, WA, 98109-1024, USA, mandrasik@fhcrc.org.
          Article
          NIHMS455230
          10.1007/s11121-013-0371-0
          3760994
          23446435

          Comments

          Comment on this article